During the reporting period, the company's total non-recurring profit and loss was 2.484 billion yuan, of which other profit and loss items that met the definition of non-recurring profit and loss were 2.898 billion yuan.
Statistics show that the compound growth rate of total operating income of Zhendong Pharmaceutical in recent three years is 14.20%, ranking 24th among the 103 companies in the chemical preparation industry that have disclosed the data of 20021year. The compound annual growth rate of net profit in recent three years is 170.3 1%, ranking 2/ 103.
The announcement shows that the company's main business is the research and development, production and sales of generic drugs and innovative drugs such as tumors, hair, digestion, urine, heart and brain, as well as the whole industrial chain of Chinese herbal medicines integrating seed seedling, planting, processing, storage and decoction pieces.
In terms of products, in the company's main business in 20021year, the income from chemical products was 3.427 billion yuan, accounting for 67.27% of the operating income; The income of traditional Chinese medicine 160 1 100 million yuan, up 39.04% year-on-year, accounting for 3 1.43% of the operating income.
In 20021year, the company's gross profit margin was 59.67%, down 2.57 percentage points year-on-year; The net interest rate was 565,438+0.23%, up 46.00 percentage points year-on-year.
By product, the gross profit rate of 202 1 for chemical medicine and traditional Chinese medicine is 57.88% and 63.22% respectively.
During the reporting period, the total sales amount of the top five customers of the company was 65.438+0.295 billion yuan, accounting for 25.42% of the total sales amount, and the total purchase amount of the top five suppliers of the company was 66.5438+0.3 billion yuan, accounting for 23.03% of the total annual purchase amount.
The data shows that in 20021year, the company's weighted average return on equity was 38.0 1%, an increase of 33.30 percentage points over the same period of last year, which has maintained growth for three consecutive years; The company's return on invested capital in 20021year was 35.94%, up by 3 1.38 percentage points over the same period of last year.
By the end of 20021,the net cash flow generated by the company's operating activities was 284 million yuan, up 2.8 16% year-on-year, mainly due to the increase in cash received from the sale of goods and the provision of services in this period; The net cash flow generated by fund-raising activities was-386 million yuan, a year-on-year decrease of 592 million yuan, mainly due to the increase in cash paid for debt repayment in this period; The net cash flow from investment activities was 349 million yuan, compared with 44160,400 yuan in the same period of last year, mainly due to the increase in net cash received from subsidiaries and other business units in the current period.
In 20021year, the cash ratio of the company's operating income was 108.70%, and the net cash ratio was 10.87%.
In terms of operational capacity, the turnover rate of the company's total assets was 0.58 times in 202 1, compared with 0.67 times in the same period last year (the industry average in 2020 was 0.52 times, and the company ranked 31104 in the same industry); The turnover rate of fixed assets is 5.2 1 time, compared with 5.04 times in the same period of last year (the industry average in 2020 is 2.69 times, and the company ranks in the same industry13/104); The company's accounts receivable turnover rate and inventory turnover rate are 5.06 times and 2.33 times respectively.
In 20021year, the company spent 2.895 billion yuan, an increase of10.93 billion yuan over the previous year; During the period, the expense rate was 56.83%, which was 1. 1 1 percentage point higher than the previous year.
In terms of major changes in assets, at the end of 20021,the company's goodwill decreased by 98.28% compared with the beginning of the year, accounting for 30.27 percentage points of the company's total assets, mainly due to the decrease in goodwill caused by the sale of its subsidiary Wen Lan Pharmaceutical and its subsidiaries in this period; Accounts receivable decreased by 22.45% compared with the beginning of the year, accounting for 6. 18 percentage points of the company's total assets, mainly due to the increase in sales receipts in the current period; Short-term loans decreased by 48.98% compared with the beginning of the period, accounting for 3.33 percentage points of the company's total assets, mainly due to the repayment of loans in this period; Fixed assets increased by 9.85% compared with the beginning of the period, accounting for 2.09 percentage points of the company's total assets, mainly due to the increase of total assets in the current period.
202 1, the company invested 258 million yuan in R&D, up 41.19% year-on-year; R&D investment accounted for 5.07% of operating income, up 65,438+0.30 percentage points compared with the same period of last year. In addition, the capitalization rate of the annual R&D investment of the company is 15.25%.
In terms of solvency, at the end of 20021,the company's asset-liability ratio was 20.20%, which was 5.7 1 percentage point lower than the same period of last year, and was lower than the industry average in recent years. The interest-bearing asset-liability ratio was 3.88%, down 3.95 percentage points from the same period last year.
According to the annual report, among the top ten tradable shareholders of the company at the end of 2002 1, the newly added shareholders were Hong Kong Securities Clearing Company Limited and Mingyu Elite1private equity investment fund, which replaced the previous Shanxi Zhendong Pharmaceutical Co., Ltd.-the first-phase employee stock ownership plan and Liu. In terms of specific shareholding ratio, Lv Zhi's shareholding increased, while Shaanxi Zhendong Health Industry Group Co., Ltd., Li Xianwei and Lin Shuyang's shareholding decreased.